Eli Lilly may be facing pressure as generics makers queue up to produce copies of its blockbuster antipsychotic drug Zyprexa (olanzapine). On 25 April 2011,the first day after Eli Lilly’s patent exclusivity expired in Spain, Ranbaxy Laboratories announced that it had launched its generic version of the treatment.
Ranbaxy launches generic olanzapine in Spain
Generics/News
|
Posted 13/05/2011
0
Post your comment
It is not surprising that generics manufacturers are waiting in the sidelines, for this is a massive opportunity. In 2010, Zyprexa’s worldwide revenues were just over US$5 billion, or nearly 22% of Eli Lilly’s full year sales. Half of those sales are estimated to come from the US, where the patent protection for Zyprexa will expire in October 2011. Other major European countries will lose patent protection in September 2011.
Ranbaxy estimated the market in Spain to be around US$210 million. It is planning to promote the generic version to physicians and pharmacists in Spain ‘with immediate effect.’ Ranbaxy’s Country Manager in Spain, Mr Pere-Lluís Sala, added that ‘the generic alternative will bring about significant savings for patients and the Spanish Health System, which has been encouraging generic prescription as a means to make health care affordable.’
Related article
2011’s biggest patent expiries
Source: Ranbaxy
Research
Japan’s drug shortage crisis: challenges and policy solutions
Saudi FDA drug approvals and GMP inspections: trend analysis
Related content
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment